Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: A metaanalysis

doi:10.3816/CLC.2007.n.035

CORC > 兰州大学 > 兰州大学 > 基础医学院 > 期刊论文

	Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: A metaanalysis
	Jiang, L; Yang, KH; Mi, DH; Liu, YL; Tian, JH; Ma, B; Tan, JY; Bai, ZG; Yang, KH (reprint author), Lanzhou Univ, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China.
刊名	CLINICAL LUNG CANCER
	2007-09
卷号	8 期号:8 页码:497-501
关键词	anemia diarrhea leukopenia nausea neutropenia thrombocytopenia toxicity vomiting
ISSN号	1525-7304
DOI	10.3816/CLC.2007.n.035
文献子类	Article
英文摘要	PURPOSE: The objective of this study was to evaluate the safety of patients with extensive small-cell lung cancer treated with irinotecan/cisplatin (IP) versus etoposide/cisplatin (EP). PATIENTS AND METHODS: This is a metaanalysis of a randomized controlled trial. The main outcome measures for safety were grade 3/4 leukopenia, grade 3 anemia, grade 3/4 thrombocytopenia, grade 3/4 neutropenia, grade 3 vomiting/nausea, grade 3/4 diarrhea, and infection. RESULTS: Three randomized controlled trials totaling 535 patients were included. Metaanalysis results are as follows: fewer patients receiving IP experienced grade 3/4 leukopenia (response rate [RR], 0.44; 95% confidence interval [Cl], 0.29-0.67), grade 3 anemia (RR, 0.65; 95% Cl, 0.43-0.99), and grade 3/4 thrombocytopenia (RR, 0.23; 95% Cl, 0.12-0.42), compared with patients receiving EP. But more patients experienced grade 3 vomiting or nausea (RR, 2.27; 95% Cl, 1.37-3.37) and grade 3/4 diarrhea (RR, 21.66; 95% Cl, 4.87-96.2). There was no significant difference between the 2 groups with regard to infection (RR, 0.75; 95% Cl, 0.54-1.04). CONCLUSION: Current clinical studies might confirm that fewer patients receiving IP experienced grade 3/4 leukopenia, grade 3 anemia, grade 3/4 thrombocytopenia, and grade 3/4 neutropenia, compared with patients receiving EP, but more experienced grade 3 vomiting/nausea and grade 3/4 diarrhea. There was no significant difference between the group receiving IP and the group receiving EP with regard to infection. Although there is convincing evidence to confirm the results mentioned herein, they still need to be confirmed by large-sample, multicenter, randomized, controlled trials.
学科主题	Oncology
出版地	DALLAS
语种	英语
WOS记录号	WOS:000249867300006
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/121374]
专题	基础医学院_期刊论文
通讯作者	Yang, KH (reprint author), Lanzhou Univ, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China.
推荐引用方式 GB/T 7714	Jiang, L,Yang, KH,Mi, DH,et al. Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: A metaanalysis[J]. CLINICAL LUNG CANCER,2007,8(8):497-501.
APA	Jiang, L.,Yang, KH.,Mi, DH.,Liu, YL.,Tian, JH.,...&Yang, KH .(2007).Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: A metaanalysis.CLINICAL LUNG CANCER,8(8),497-501.
MLA	Jiang, L,et al."Safety of irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive-stage small-cell lung cancer: A metaanalysis".CLINICAL LUNG CANCER 8.8(2007):497-501.